He, Jianming http://orcid.org/0000-0002-5015-3713
Berringer, Heather
Heeg, Bart
Ruan, Haoyao
Kampfenkel, Tobias
Dwarakanathan, Harikumaran R.
Johnston, Stephen
Mendes, João
Lam, Annette
Bathija, Sacheeta
Mackay, Emma K.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
https://doi.org/10.1007/s12325-022-02226-x
Documents that mention this clinical trial
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
https://doi.org/10.1200/jco.21.02734
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
https://doi.org/10.1007/s12325-022-02226-x
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
https://doi.org/10.1007/s12325-022-02226-x
Funding for this research was provided by:
Janssen Global Services, LLC
Article History
Received: 14 March 2022
Accepted: 15 June 2022
First Online: 22 July 2022